health
Melanoma study links major response to 98% five-year survival
A pooled analysis of 1,038 patients found 86.5% five-year overall survival after neoadjuvant immune checkpoint inhibitors for resectable melanoma. Among patients whose tumours had a major pathological response, estimated five-year survival was 98%.